Resistance Rates of Mycobacterium tuberculosis Complex Isolates to Primary Anti-tuberculosis Drugs: A 5-Year Retrospective Study
Öz
Background/Aim: Tuberculosis remains a major global health problem with a high morbidity and mortality rate, approximately a quarter of the population is infected with tuberculosis. Drug susceptibility testing is an essential tool for identifying and managing drug-resistant tuberculosis. This study was conducted to evaluate the drug susceptibility pattern of Mycobacterium tuberculosis complex strains isolated from a university hospital.
Methods: A total of 10900 samples sent to the microbiology laboratory with the suspicion of tuberculosis clinically between January 2018 and January 2022 were analyzed retrospectively. The automated BACTEC MGIT 960 (Becton Dickinson, USA) was used for sample culture and susceptibility testing. The obtained data were statistically analyzed with the Statistical Package for Social Sciences (SPSS version 20).
Results: Out of the 154 isolated positive samples, males and females constituted equal parts of the study population (50%). The majority of tuberculosis cases were in the age group 56–75 years (42.2%), Pulmonary TB was detected in (90.3%) of the patients, while extrapulmonary TB cases were observed in (9.7%). As a result of susceptibility studies on positive samples, isoniazid resistance was 5.2%; streptomycin resistance 1.3%; ethambutol resistance was detected at a rate of 0.6%, while no rifampicin resistant sample was found. Both streptomycin and isoniazid resistance were seen together in 1.3% of the samples.
Conclusion: A similar resistance pattern of the first-line antituberculosis drugs was observed in other studies conducted in different provinces of Turkey. The absence of multi-drug resistant and extensively drug-resistant tuberculosis in our study indicates that the tuberculosis surveillance program implemented in our region was successful.
Anahtar Kelimeler
Mycobacterium tuberculosis complex, tuberculosis, anti-tuberculosis drug, drug susceptibility testing.
Kaynakça
- Diriba G, Alemu A, Tola HH, Eshetu K, Yenew B, Amare M, et al. Detection of Mycobacterium tuberculosis and rifampicin resistance by Xpert® MTB/RIF assay among presumptive tuberculosis patients in Addis Ababa, Ethiopia from 2014 to 2021. IJID Regions. 2022; 5: 97–103.
- Sah SK, Bhattarai PR, Shrestha A, Dhami D, Guruwacharya D, Shrestha R. Rifampicin-resistant Mycobacterium tuberculosis by Gene-Xpert MTB/RIF and Associated Factors among Presumptive Pulmonary Tuberculosis Patients in Nepal. Infect Drug Resist. 2020;13:2911–9.
- Lavania M, Kunja Mohanty K, Sha W, Ameni G. Drug sensitivity of clinical isolates of Mycobacterium tuberculosis and its association with bacterial genotype in the Somali region, Eastern Ethiopia. Front Public Health. 2022;10:1–10.
- Global Tuberculosis Report 2022 [Internet]. 2022. Available from: http://apps.who.int/bookorders.
- Tuberculosis surveillance and monitoring in Europe 2022 – 2020 data. [Internet]. 2022. Available from: http://apps.who.int/bookorders.
- Silas G, Ollor OA, Agi VN, Nwokah EG, Wokem GN, Enoch AS. Resistance Profile of Mycobacterial Strains Causing Cluster Pulmonary Infection in Bayelsa State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(1):1–7.
- Terzi A, Aydemir Ö, Karakeçe E, Köroğlu M, Altındiş M. Changes in antituberculosis drug resistance rates of M. tuberculosis complex isolates by years; Sakarya. Online Türk Sağlık Bilimleri Dergisi. 2019;4(1):47–56.
- Farra A, Manirakiza A, Yambiyo BM, Zandanga G, Lokoti B, Berlioz-Arthaud A, et al. Surveillance of rifampicin resistance with GeneXpert MTB/RIF in the National Reference Laboratory for tuberculosis at the Institut Pasteur in Bangui, 2015-2017. In Open forum infectious diseases (Vol. 6, No. 3, p. ofz075). US: Oxford University Press, 2019.
- Iem V, Dean A, Zignol M, Vongvichit P, Inthavong D, Siphanthong S, et al. Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey. Tropical Medicine and International Health. 2019; 24(4):421–31.
- Yılmaz A, Afşin D. Investigation of the Sensitivity of Mycobacterium Tuberculosis Strains Isolated from Various Clinical Samples in Eastern Turkey to Major Anti-tuberculosis Drugs. Journal of Contemporary Medicine. 2021;11(1):92–6.